Stock Thread (130 Viewers)

[BassNBrew]

Well, in mine andy wife's Roth account we are at like 85% cash.
So......buy up a bunch tomorrow? Wait for a further drop??

What do you think the absolute downside is?

Zero clue.
This isn't a huge amount of money though. Our Roth accounts combined are only like 1/10 what I have in my 403b, which just stays 100% equities.

If you keep it in cash forever then it will stay small. When NVDA is $160 at the end of the year are you won't remember if you bought it at $105, $100, $90, or even $80, but you will remember that you screwed up by not buying it.

Bump for a reminder the next time a gift horse shows up.

 

[BassNBrew]

Me: when Nvda hits 150 im gonna take my tariff shares off the table

*nvda hits 150*

Also me: it’s just gonna keep going up forever baby!

I never sell when I hit my target price. I don’t even know why I do that.

I wonder which smart Wall Street company sold those tariff shares to a dumb retail investor like you

 

[landrys hat]

Anybody still holding some QS?

 

[The Z Machine]

Yeah, I'm pretty stoked my NVDA shares are up 42% from when I bought them this year. MSFT up like 35% too is pretty good

 

[Capella]

Me: when Nvda hits 150 im gonna take my tariff shares off the table

*nvda hits 150*

Also me: it’s just gonna keep going up forever baby!

I never sell when I hit my target price. I don’t even know why I do that.

I wonder which smart Wall Street company sold those tariff shares to a dumb retail investor like you

lol Schwab called me a few weeks ago peddling some investor service. Told them I was good.

 

[The Z Machine]

Me: when Nvda hits 150 im gonna take my tariff shares off the table

*nvda hits 150*

Also me: it’s just gonna keep going up forever baby!

I never sell when I hit my target price. I don’t even know why I do that.

I wonder which smart Wall Street company sold those tariff shares to a dumb retail investor like you

lol Schwab called me a few weeks ago peddling some investor service. Told them I was good.

You told them, "Nah, we good. I got Todem."

 

[BassNBrew]

Anybody still holding some QS?

Yup, about 190 shares. Down 82% or roughly $5000. Thanks for reminding me what an idiot I am. Its like a Greek shipping company

Me: when Nvda hits 150 im gonna take my tariff shares off the table

*nvda hits 150*

Also me: it’s just gonna keep going up forever baby!

I never sell when I hit my target price. I don’t even know why I do that.

I wonder which smart Wall Street company sold those tariff shares to a dumb retail investor like you

lol Schwab called me a few weeks ago peddling some investor service. Told them I was good.

Lol. I had one of those guys called me recently and told him I was up 60% on the year and that I would be open to services if you could guarantee a return better than that. That number is now over 70%.

That that Schwab service might be worthwhile to you. You could just fade all their advice.

 

[Capella]

Me: when Nvda hits 150 im gonna take my tariff shares off the table

*nvda hits 150*

Also me: it’s just gonna keep going up forever baby!

I never sell when I hit my target price. I don’t even know why I do that.

I wonder which smart Wall Street company sold those tariff shares to a dumb retail investor like you

lol Schwab called me a few weeks ago peddling some investor service. Told them I was good.

You told them, "Nah, we good. I got Todem."

I did tell him to check my returns lol

 

[BassNBrew]

Me: when Nvda hits 150 im gonna take my tariff shares off the table

*nvda hits 150*

Also me: it’s just gonna keep going up forever baby!

I never sell when I hit my target price. I don’t even know why I do that.

I wonder which smart Wall Street company sold those tariff shares to a dumb retail investor like you

lol Schwab called me a few weeks ago peddling some investor service. Told them I was good.

You told them, "Nah, we good. I got Todem."

I did tell him to check my returns lol

Maybe you misunderstood and he was trying to offer you a job

 

[BassNBrew]

I mean really how hard could it be to get hired at an investment firm

Interviewer: Mr. Capella, what could you bring to our firm

Mr. Capella: stonks go up.

Interviewer: Mr. Capella you’re hired

 

[Chadstroma]

Finally something I acted on and did well... AVAV jumped 23% today and I am up nearly 60% on it after a short period

 

[Chadstroma]

Finally something I acted on and did well... AVAV jumped 23% today and I am up nearly 60% on it after a short period

KTOS was my other purchase around the same time that ha performed almost as well for me.

Yea for making a good decision out if the bad

 

[GreenNGold]

Finally something I acted on and did well... AVAV jumped 23% today and I am up nearly 60% on it after a short period

AVAV has been one of my favorite stocks for awhile, and I think with their smaller market cap (compared to other defense companies) and both drone warfare and drone defense becoming more important, they still have a lot of room to grow.

 

[BassNBrew]

Micron reported better-than-expected earnings and revenue on Wednesday and issued a forecast that also topped analysts’ estimates. The stock initially popped in extended trading before paring most of its gains.

Here’s how the company did in comparison with the LSEG consensus:

• Earnings per share: $1.91, adjusted vs. $1.60 expected
• Revenue: $9.3 billion vs. $8.87 billion expected

Micron said revenue in the current period, its fiscal fourth quarter, will be about $10.7 billion, up 38% from $7.75 billion a year earlier and ahead of the $9.9 billion average analyst estimate, according to LSEG.

Data center revenue more than doubled in the third quarter, Micron said, as total sales jumped 37% from $6.81 billion a year ago. The company has seen soaring demand in the high bandwidth memory, or HBM, market due to the artificial intelligence boom.

If total obliteration describes the Iran nuclear program I'm not sure they're words for this report. At a $63.61 cost basis this has been better than a chicken dinner.

 

[BassNBrew]

With industries like technology and consumer discretionary driving Thursday’s market meltdown following President Donald Trump’s rollout of new tariffs, CNBC’s Jim Cramer points investors to the same sectors that rose after the dot-com bubble burst in 2000.

Stocks cratered on Thursday, with the Dow falling nearly 4%, the S&P 500 shedding 4.8%, the Nasdaq plunging almost 6% and the Russell 2000 losing 6.4%. Still, Cramer said, there are some companies that will do better than others in the era of Trump tariffs.




“You buy stocks that have a couple of important characteristics, encapsulated by this one sentence: You want stocks of domestic companies with pricing power and with no slackening in demand or credit risk that do well in a slowdown,” Cramer said.

Cramer highlighted companies in health-related industries such as drug distribution, insurance and pharmaceuticals. He said pharmaceuticals especially offer “slow and steady” growth that will hold up in the new market. Among the names Cramer recommended were Cardinal Health, Bristol-Myers Squibb and UnitedHealth.

Utilities, lower-priced retailers, telecommunications and consumer packaged goods will also do well in a slower economic environment, Cramer said. Some of his top picks in those sectors were Duke Energy, TJX, AT&T and Procter & Gamble.

Companies in financial technology, like Intercontinental Exchange, and real estate, like Ventas, that have little-to-no credit risk are also attractive stocks right now, Cramer added.

While many of these plays are from the post-dotcom bubble strategy, Cramer also noted companies that might specifically benefit from the Trump tariffs. Defense contractors like Boeing and Lockheed Martin could potentially see gains if countries looking to appease Trump place large orders with those businesses, Cramer said.




It hurts, Cramer said, to turn away from sectors that have soared in the current market, like tech and enterprise software. But the April 2000 playbook is back in charge, he said, and that limits the options for investors.

“I know that there’s nothing more exciting to invest in than tech, and tech will have its chance again in the future,” Cramer said. “You now know what worked back then. And I bet the same groups will work once again.”

 

[landrys hat]

Anybody still holding some QS?

Yup, about 190 shares. Down 82% or roughly $5000. Thanks for reminding me what an idiot I am. Its like a Greek shipping company

Up 30% two days in a row.

 

[Gamma1210]

I believe some here have discussed pharmaceuticals stock VRTX. They dropped incredible news on Friday of their phase 1/2 study to cure type 1 diabetes. No clue why the stock didn’t skyrocket. It actually lost over 1%. Potential cure for type 1 (then maybe type 2?) diabetes. What am I missing? Already overvalued?

https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes

It's my biggest holding - I jumped in at $200 and have been riding high with this one ever since.

The "cure" for Type 1 diabetes has been the stretch goal for VRTX for quite some time. They have a test subject who has been able to live without insulin for quite some time; why this isn’t pushing the "cure" forward faster, I'm not sure. But they have made acquisitions and pumped a ton of research into this so hopefully people like my 21 year old son who has T1D can see this "cure" in his lifetime. Not sure if he'll be able to afford it, but it would be a game changer if this happens for humankind.

The cure for Type 2 is a simplistic - stop poisoning your body with sugars and fats and drop weight. It's why we have such a proliferation of weight loss drugs now - these were all designed for folks who lack the discipline to not over-indulge and now even folks without Type 2 are using the meds.

VRTX is the world leader in treatment for cystic fibrosis. That's their main driver. They also have been pushing hard for non-opiode pain relievers which would be another huge success if proven to be effective.

Lots to love here.

Reminding myself to respond later, this is in my field.

Ok I have a few minutes, IMO a few reasons this isn't really moving the needle even though they are really exciting results.

1. Simplest- this is a Phase 1/2 and there is a long way to go in clinical development before this would be approved.
2. Right now the advanced therapy (Cell and Gene Therapy) market is in shambles. Like no investment flowing in and good news isn't moving the needle. There are a ton of companies in the space trading well below cash on hand and companies seem to be folding by the week. I don't think the market/ investors is putting any weight in a cell therapy for a company this size.
3. There is obviously a tremendous amount of research in this space and the big issue here is that patients need immunosuppression so their bodies don't reject the cells. There is a lot of work ongoing to get past this. Vertex just killed a trial of a device/ cell combo they thought would eliminate the need for immunosuppression. https://www.clinicaltrialsarena.com...tes-cell-therapy-after-trial-failure/?cf-view
Also there are other methods being evaluated to deliver the cells without immunosuppression https://ir.sana.com/news-releases/n...type 1 diabetes without any immunosuppression.

Not endorsing that company just showing a lot of work out there in a "Version 2.0" that could obsolete the VRTX program. All just IMO

 

[urbanhack]

We are working with Vertex on a new regulatory monitoring software tool for tracking and managing guidance and regulatory changes from all global health authorities. They our are first beta customer for this product.

 

[BassNBrew]

Nike did something good. Picked up a small tariff tantrum position that should have been more AMD or NVDA.

 

[BassNBrew]

Anybody still holding some QS?

Yup, about 190 shares. Down 82% or roughly $5000. Thanks for reminding me what an idiot I am. Its like a Greek shipping company

Up 30% two days in a row.

Only down 73% now.

 

[General Malaise]

We are working with Vertex on a new regulatory monitoring software tool for tracking and managing guidance and regulatory changes from all global health authorities. They our are first beta customer for this product.

Whoa